Hasil Pencarian - Kimberly T. Webster

  • Menampilkan 1 - 8 hasil dari 8
Perbaiki Hasil
  1. 1
    Written Verb Naming Improves After tDCS Over the Left IFG in Primary Progressive Aphasia

    Written Verb Naming Improves After tDCS Over the Left IFG in Primary Progressive Aphasia oleh Amberlynn S. Fenner, Kimberly T. Webster, Kimberly T. Webster, Bronte N. Ficek, Constantine E. Frangakis, Constantine E. Frangakis, Constantine E. Frangakis, Kyrana Tsapkini, Kyrana Tsapkini

    Diterbitkan 2019-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Neural Correlates of Letter and Semantic Fluency in Primary Progressive Aphasia

    Neural Correlates of Letter and Semantic Fluency in Primary Progressive Aphasia oleh Marianna Riello, Constantine E. Frangakis, Bronte Ficek, Kimberly T. Webster, John E. Desmond, Andreia V. Faria, Argye E. Hillis, Kyrana Tsapkini

    Diterbitkan 2021-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Content validation of the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 (NFLymSI-18) in indolent B-cell non-Hodgkin’s lymphoma

    Content validation of the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 (NFLymSI-18) in indolent B-cell non-Hodgkin’s lymp... oleh Courtney N. Hurt, Karen Kaiser, Sara Shaunfield, Kimberly A. Webster, Karen Keating, Lara Boyken, Sara Duffey, Jessica Garcia, David Cella

    Diterbitkan 2024-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Protocol for a type 2 hybrid effectiveness-implementation study expanding, implementing and evaluating electronic health record-integrated patient-reported symptom monitoring in a multisite cancer centre

    Protocol for a type 2 hybrid effectiveness-implementation study expanding, implementing and evaluating electronic health record-integrated patient-reported symptom monitoring in a... oleh David Cella, Justin D Smith, Frank J Penedo, Sofia F Garcia, Michael Kallen, Kimberly A Webster, Madison Lyleroehr, Sheetal Kircher, Michael Bass

    Diterbitkan 2022-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    The effect of tDCS on functional connectivity in primary progressive aphasia

    The effect of tDCS on functional connectivity in primary progressive aphasia oleh Bronte N. Ficek, Zeyi Wang, Yi Zhao, Kimberly T. Webster, John E. Desmond, Argye E. Hillis, Constantine Frangakis, Andreia Vasconcellos Faria, Brian Caffo, Kyrana Tsapkini

    Diterbitkan 2018-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    “The effect of tDCS on functional connectivity in primary progressive aphasia” NeuroImage: Clinical, volume 19 (2018), pages 703–715

    “The effect of tDCS on functional connectivity in primary progressive aphasia” NeuroImage: Clinical, volume 19 (2018), pages 703–715 oleh Bronte N. Ficek, Zeyi Wang, Yi Zhao, Kimberly T. Webster, John E. Desmond, Argye E. Hillis, Constantine Frangakis, Andreia Vasconcellos Faria, Brian Caffo, Kyrana Tsapkini

    Diterbitkan 2019-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    A mixed methods evaluation of patient perspectives on the implementation of an electronic health record-integrated patient-reported symptom and needs monitoring program in cancer care

    A mixed methods evaluation of patient perspectives on the implementation of an electronic health record-integrated patient-reported symptom and needs monitoring program in cancer c... oleh Madison J. Lyleroehr, Kimberly A. Webster, Laura M. Perry, Elijah A. Patten, Jackelyn Cantoral, Justin D. Smith, David Cella, Frank J. Penedo, Sofia F. Garcia

    Diterbitkan 2024-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria.

    Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria. oleh John Devin Peipert, Austin G Kulasekararaj, Anna Gaya, Saskia M C Langemeijer, Susan Yount, F Ataulfo Gonzalez-Fernandez, Emilio Ojeda Gutierrez, Christa Martens, Amy Sparling, Kimberly A Webster, David Cella, Ioannis Tomazos, Masayo Ogawa, Caroline I Piatek, Richard Wells, Flore Sicre de Fontbrune, Alexander Röth, Lindsay Mitchell, Anita Hill, Karen Kaiser

    Diterbitkan 2020-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: